
Conivate-OZ Cream by Coniak Lifesciences is a topical combination formulation containing Ofloxacin, Ornidazole, Itraconazole and Clobetasol Propionate. The formulation combines antibacterial, antiprotozoal, antifungal and corticosteroid ingredients for external application.
Ofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, helping control susceptible bacteria. Ornidazole is a nitroimidazole antimicrobial agent with activity against certain anaerobic bacteria and protozoal organisms.
Itraconazole is an antifungal medicine that interferes with ergosterol synthesis, an essential process involved in fungal cell membrane formation. However, the clinical effectiveness of Itraconazole in this specific topical combination has not been established.
Clobetasol Propionate is a highly potent topical corticosteroid that suppresses inflammation, redness and itching. Its presence requires particular caution because strong corticosteroids can worsen fungal skin infections, mask symptoms and cause skin thinning with inappropriate use.
Conivate-OZ Cream should only be considered for a specifically diagnosed condition when a qualified dermatologist determines that the combination is appropriate. Its safety, effectiveness and applicable regulatory status should be verified before use or marketing.
Prices are indicative and set by the listing company. Confirm net rates, packing and stock availability directly with the supplier.
Coniak Lifesciences is a WHO-GMP and ISO 9001:2015 certified pharmaceutical and PCD (Propaganda Cum Distribution) pharma franchise company based in Panchkula, Haryana, India.
Key Company Details
• Established: 2014
• Headquarters: Plot No. 208, Industrial Area, Phase-1, Panchkula, Haryana, 134113
• Certifications: WHO-GMP and ISO certified
• Phone Number: +91-9570599567
• Official Website: Coniak Lifesciences
Core Operations & Offerings
• Product Formulations: Manufactures and supplies allopathic, herbal, Ayurvedic, and nutraceutical medicines.
• Dosage Forms: Tablets, capsules, softgels, syrups, dry syrups, injections, ointments, protein powders, pediatric drops, and dental solutions.
• Featured Brands: Conipraz LSR, Itrarap 100, Conisure P, Cincred 25, and Coniphage-N.
• Business Model: Offers pan-India PCD pharma franchise opportunities with monopoly rights alongside third-party and contract manufacturing services.
• Investment Range: Franchise partnerships typically require an initial investment ranging from ₹50,000 to ₹1.5 lakh depending on the product range.
Would you like details on their product catalog, monopoly territory availability, or franchise terms?